TMDX - TransMedics Group, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
26.49
+0.47 (+1.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.02
Open26.04
Bid26.23 x 900
Ask28.44 x 800
Day's Range25.32 - 26.95
52 Week Range19.76 - 31.54
Volume178,634
Avg. Volume390,938
Market Cap558.772M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.33
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    TransMedics Reports First Quarter 2019 Financial Results

    ANDOVER, Mass., June 11, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • ACCESSWIRE6 days ago

    TransMedics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / TransMedics Group, Inc. (NASDAQ: TMDX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on June 11, 2019 at 4:30 PM ...

  • GlobeNewswire14 days ago

    TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it has received an FDA PMA approval for expanded clinical indications of the Organ Care System (OCS) Lung.  This approval will enable the OCS Lung System to be used for the preservation and ex-vivo assessment of both standard criteria donor lungs as well as the larger pool of donor lungs initially deemed unacceptable for procurement and transplantation based on limitations of cold static preservation. This approval will also enable the OCS Lung System to be used with both donors after brain death (DBD) and donors after circulatory death (DCD).  Prior to this latest FDA approval, the OCS Lung System was approved for standard criteria lungs from DBD donors only.  Based on this FDA PMA approval, TransMedics will expand its post-market Thoracic Organ Perfusion (TOP) Registry to collect long-term post-market data from recipients of all OCS Lung preserved standard criteria and initially deemed unacceptable donor lungs.

  • GlobeNewswire18 days ago

    TransMedics to Report First Quarter 2019 Financial Results on June 11, 2019

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2019 after market close on Tuesday, June 11, 2019. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 2475974.

  • GlobeNewswirelast month

    TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the closing of its initial public offering of 6,543,500 shares of its common stock at an initial public offering price of $16.00 per share, including 853,500 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The shares commenced trading on The Nasdaq Global Market on May 2, 2019 under the ticker symbol “TMDX.” All of the shares were sold by TransMedics. Morgan Stanley and J.P. Morgan acted as joint lead book-running managers for the offering.

  • Benzinga2 months ago

    TransMedics Group IPO: What You Need To Know

    Looking to inject new life into your medtech portfolio? One company hits the market this week in an effort to keep your pulse and its pulse pumping. The IPO Transmedics Group, Inc. will issue 4.7 million ...